Study of the Efficacy and Safety of ICP-332 in Participants With Prurigo Nodularis

Recruiting

Phase 2

ICP-332Study of the Efficacy and Safety of ICP-332 in Participants With Prurigo Nodularis

Sponsor:

Beijing InnoCare Pharma Tech Co., Ltd.

Code:

NCT07236099

Conditions

Prurigo Nodularis (PN)

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

ICP-322

Placebo

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-04-21. This information was provided to ClinicalTrials.gov by Beijing InnoCare Pharma Tech Co., Ltd. on 2026-04-09.